Efficacy of famotidine for the prevention of exercise-induced gastritis in racing alaskan sled dogs

Journal of Veterinary Internal Medicine

Volumn 21, Issue 5, 2007, Pages 924-927

  Williamson, Katherine K ^a   Willard, Michael D ^a,b   McKenzie, Erica C ^a   Royer, Christopher M ^a   Payton, Mark E ^a   Davis, Michael S ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Exercise; Gastric ulcers; Gastroscopy; Omeprazole

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ANIMAL; ANIMAL DISEASE; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; GASTRITIS; GASTROSCOPY; MALE; METABOLISM; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; DOG DISEASES; DOGS; FAMOTIDINE; FEMALE; GASTRITIS; GASTROSCOPY; HISTAMINE H2 ANTAGONISTS; MALE; PHYSICAL CONDITIONING, ANIMAL; PILOT PROJECTS;

ANIMALIA; CANIS FAMILIARIS;

EID: 34848830854     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[924:EOFFTP]2.0.CO;2     Document Type: Article

References (15)

1. Davis MS, Willard M, Nelson S, et al. Prevalence of gastric lesions in racing Alaskan sled dogs. J Vet Intern Med 2003;17: 311-314.
2. Davis MS, Willard M, Nelson S, et al. Efficacy of omeprazole for the prevention of exercise-induced gastritis in racing Alaskan sled dogs. J Vet Intern Med 2003;17:163-166.
3. Davis MS, Willard MD, Williamson KK, et al. Sustained strenuous exercise increases intestinal permeability in racing Alaskan sled dogs. J Vet Intern Med 2005;19:34-39.
4. Davis MS, Willard M, Williamson KK, et al. The temporal relationship between gastrointestinal protein loss, gastric ulceration or erosion, and strenuous exercise in racing Alaskan sled dogs. J Vet Intern Med 2006;20:835-839.
5. Vatistas NJ, Snyder JR, Nieto J, et al. Acceptability of a paste formulation and efficacy of high dose omeprazole in healing gastric ulcers in horses maintained in race training. Equine Vet J Suppl 1999;71-76.
6. Choi SJ, Kim YS, Chae JR, et al. Effects of ranitidine for exercise induced gastric mucosal changes and bleeding. World J Gastroenterol 2006;12:2579-2583.
7. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: Cohort studies. Br J Clin Pharmacol 2000;50:366-372.
8. Zendelovska D, Stafilov T. Development of an HPLC method for the determination of ranitidine and cimetidine in human plasma following SPE. J Pharm Biomed Anal 2003;33: 165-173.
9. Agresti A. Categorical Data Analysis. New York, NY: J Wiley; 1990:22.
10. Pilbrant A, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol Suppl 1985;108: 113-120.
11. Hinchcliff KW, Reinhart GA, Burr JR, et al. Metabolizable energy intake and sustained energy expenditure of Alaskan sled dogs during heavy exertion in the cold. Am J Vet Res 1997;58: 1457-1462.
12. Grandjean D. The sled dog athlete. In Schmidt KE, ed. The Musher and Veterinary Handbook. Wakefield, MA: International Sleddog Veterinary Medical Association; 1998:15-27.
13. Schwartz JI, Yeh KC, Berger ML, et al. Novel oral medication delivery system for famotidine. J Clin Pharmacol 1995;35:362-367.
14. Nagaya H, Inatomi N, Satoh H. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs. Jpn J Pharmacol 1991;55:425-436.
15. Yeh KC, Chremos AN, Lin JH, et al. Single dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. Biopharm Drug Disp 1987;8: 549-560.